LFCR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Lifecore Biomedical, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. (“Lifecore” or “the Company”) (NASDAQ: LFCR) and certain of its officers.
- 09/27/2024
|
Lifecore Biomedical, Inc. Is Being Sued For Violating Securities Laws And Affected Shareholders Are Invited To Reach Out To The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / September 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.
- 09/27/2024
|
FINAL DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore
- Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Lifecore To Contact Him Directly To Discuss Their Options NEW YORK CITY, NY / ACCESSWIRE / September 27, 2024 / If you suffered losses exceeding $75,000 in Lifecore between October 7, 2020 and March 19, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ:LFCR) and reminds investors of the September 27, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
- 09/27/2024
|
FINAL LFCR DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Lifecore Biomedical, Inc. Investors to Join the Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / September 27, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").
- 09/27/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lifecore Biomedical, Inc. of Class Action Lawsuit and Upcoming Deadlines - LFCR
- NEW YORK, NY / ACCESSWIRE / September 27, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ:LFCR) and certain officers. The class action, filed in the United States District Court for the District of Minnesota, and docketed under 24-cv-03028, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 09/27/2024
|
LFCR DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Lifecore Biomedical, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important September 27 Deadline in Securities Class Action – LFCR
- NEW YORK, Sept. 26, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lifecore Biomedical, Inc. (NASDAQ: LFCR) between October 7, 2020 and March 19, 2024, both dates inclusive (the “Class Period”), of the important September 27, 2024 lead plaintiff deadline.
- 09/26/2024
|
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Lifecore Biomedical, Inc. (LFCR)
- LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming September 27, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Lifecore Biomedical, Inc. (“Lifecore” or the “Company”) (NASDAQ: LFCR) securities between October 7, 2020 and March 19, 2024, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. On March 20, 2024, Lifecore released its Annual R.
- 09/26/2024
|
The Schall Law Firm Urges Investors To Join A Securities Fraud Case Against Lifecore Biomedical Inc
- LOS ANGELES, CA / ACCESSWIRE / September 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.
- 09/26/2024
|
FINAL REMINDER LFCR DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Lifecore Biomedical, Inc. Investors to Participate in the Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / September 26, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").
- 09/26/2024
|
LFCR Investors Have Opportunity to Lead Lifecore Biomedical, Inc. Securities Fraud Lawsuit
- BENSALEM, Pa. , Sept. 25, 2024 /PRNewswire/ -- Law Offices of Howard G.
- 09/25/2024
|
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore
- Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Lifecore To Contact Him Directly To Discuss Their Options
- 09/25/2024
|
Lifecore Biomedical to Participate at Upcoming Industry Conferences and Events
- CHASKA, Minn., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate at four upcoming industry events. Details of the company's activities at these events are as follows:
- 09/25/2024
|
Lifecore Biomedical, Inc. Is Being Sued For Violating Securities Laws And Shareholders Are Invited To Reach Out To The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / September 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.
- 09/25/2024
|
LFCR Shareholders Have Opportunity to Lead Lifecore Biomedical, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
- NEW YORK, NY / ACCESSWIRE / September 25, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").
- 09/25/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lifecore Biomedical, Inc. of Class Action Lawsuit and Upcoming Deadlines - LFCR
- NEW YORK , Sept. 25, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ: LFCR) and certain officers.
- 09/25/2024
|
LFCR Investors Have Opportunity to Lead Lifecore Biomedical, Inc. Securities Fraud Lawsuit with the Schall Law Firm
- LOS ANGELES , Sept. 25, 2024 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ: LFCR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
- 09/25/2024
|
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Lifecore Biomedical, Inc. (LFCR)
- LOS ANGELES, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming September 27, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Lifecore Biomedical, Inc. (“Lifecore” or the “Company”) (NASDAQ: LFCR) securities between October 7, 2020 and March 19, 2024, inclusive (the “Class Period”).
- 09/24/2024
|
The Schall Law Firm Urges Investor Participation In A Securities Fraud Case Against Lifecore Biomedical Inc
- LOS ANGELES, CA / ACCESSWIRE / September 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.
- 09/24/2024
|
LFCR Investors Have Opportunity to Lead Lifecore Biomedical, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
- NEW YORK, NY / ACCESSWIRE / September 24, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").
- 09/24/2024
|
LFCR FINAL DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Lifecore Biomedical, Inc. Investors to Secure Counsel Before Important September 27 Deadline in Securities Class Action – LFCR
- NEW YORK, Sept. 23, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lifecore Biomedical, Inc. (NASDAQ: LFCR) between October 7, 2020 and March 19, 2024, both dates inclusive (the “Class Period”), of the important September 27, 2024 lead plaintiff deadline.
- 09/23/2024
|
Lifecore Biomedical, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. September 27, 2024 Deadline to file Lead Plaintiff Motion
- Investors can contact the law firm at no cost to learn more about recovering their losses
- 09/23/2024
|
Lifecore Biomedical, Inc. Is Being Sued For Possible Securities Law Violations And Shareholders Are Invited To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / September 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.
- 09/23/2024
|
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore
- Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Lifecore To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Lifecore between October 7, 2020 and March 19, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Sept.
- 09/23/2024
|
LFCR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Lifecore Biomedical, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / September 23, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").
- 09/23/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lifecore Biomedical, Inc. of Class Action Lawsuit and Upcoming Deadlines - LFCR
- NEW YORK, NY / ACCESSWIRE / September 23, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ:LFCR) and certain officers. The class action, filed in the United States District Court for the District of Minnesota, and docketed under 24-cv-03028, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 09/23/2024
|
LFCR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Lifecore Biomedical, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- NEW YORK, Sept. 22, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. (“Lifecore” or “the Company”) (NASDAQ: LFCR) and certain of its officers.
- 09/22/2024
|
The Schall Law Firm Urges Investor Participation In A Securities Fraud Case Against Lifecore Biomedical Inc
- LOS ANGELES, CA / ACCESSWIRE / September 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.
- 09/22/2024
|
LFCR Deadline: LFCR Investors Have Opportunity to Lead Lifecore Biomedical, Inc. Securities Fraud Lawsuit
- NEW YORK , Sept. 22, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lifecore Biomedical, Inc. (NASDAQ: LFCR) between October 7, 2020 and March 19, 2024, both dates inclusive (the "Class Period"), of the important September 27, 2024 lead plaintiff deadline.
- 09/22/2024
|
LFCR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Lifecore Biomedical, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / September 22, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").
- 09/22/2024
|
Lifecore Biomedical, Inc. Is Being Sued For Securities Related Infractions And Impacted Stockholders Are Invited To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / September 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.
- 09/21/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lifecore Biomedical, Inc. of Class Action Lawsuit and Upcoming Deadlines - LFCR
- NEW YORK, NY / ACCESSWIRE / September 21, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ:LFCR) and certain officers. The class action, filed in the United States District Court for the District of Minnesota, and docketed under 24-cv-03028, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 09/21/2024
|
LFCR Investors Have Opportunity to Lead Lifecore Biomedical, Inc. Securities Fraud Lawsuit
- LOS ANGELES , Sept. 20, 2024 /PRNewswire/ -- The Law Offices of Frank R.
- 09/20/2024
|
LFCR DEADLINE NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Lifecore Biomedical, Inc. Investors to Secure Counsel Before Important September 27 Deadline in Securities Class Action – LFCR
- NEW YORK, Sept. 20, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lifecore Biomedical, Inc. (NASDAQ: LFCR) between October 7, 2020 and March 19, 2024, both dates inclusive (the “Class Period”), of the important September 27, 2024 lead plaintiff deadline.
- 09/20/2024
|
The Schall Law Firm Encourages Investors To Take Part In A Case Against Lifecore Biomedical Inc For Securities Fraud
- LOS ANGELES, CA / ACCESSWIRE / September 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.
- 09/20/2024
|
LFCR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Lifecore Biomedical, Inc. Investors Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / September 20, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").
- 09/20/2024
|
Lifecore Biomedical, Inc. Is Being Sued For Securities Law Violations And Affected Shareholders Are Urged To Help The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / September 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.
- 09/19/2024
|
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore
- Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Lifecore To Contact Him Directly To Discuss Their Options
- 09/19/2024
|
LFCR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Lifecore Biomedical, Inc. Investors Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / September 19, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").
- 09/19/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lifecore Biomedical, Inc. of Class Action Lawsuit and Upcoming Deadlines - LFCR
- NEW YORK, NY / ACCESSWIRE / September 19, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ:LFCR) and certain officers. The class action, filed in the United States District Court for the District of Minnesota, and docketed under 24-cv-03028, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 09/19/2024
|
Lifecore Biomedical Announces High-Speed, Multi-Purpose 5-Head Isolator Filler is GMP-Ready and Operational
- Installation and Qualification Successfully Completed for Closed-System Filler for Pre-Filled Syringes, Vials, and Cartridges
- 09/19/2024
|
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Lifecore Biomedical, Inc. (LFCR)
- LOS ANGELES, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming September 27, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Lifecore Biomedical, Inc. (“Lifecore” or the “Company”) (NASDAQ: LFCR) securities between October 7, 2020 and March 19, 2024, inclusive (the “Class Period”).
- 09/18/2024
|
The Schall Law Firm Invites Investor Participation In A Securities Fraud Case Against Lifecore Biomedical Inc
- LOS ANGELES, CA / ACCESSWIRE / September 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.
- 09/18/2024
|
LFCR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Lifecore Biomedical, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / September 18, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").
- 09/18/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lifecore Biomedical, Inc. of Class Action Lawsuit and Upcoming Deadlines - LFCR
- NEW YORK , Sept. 17, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ: LFCR) and certain officers.
- 09/17/2024
|
LFCR Deadline: LFCR Investors Have Opportunity to Lead Lifecore Biomedical, Inc. Securities Fraud Lawsuit
- NEW YORK , Sept. 17, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lifecore Biomedical, Inc. (NASDAQ: LFCR) between October 7, 2020 and March 19, 2024, both dates inclusive (the "Class Period"), of the important September 27, 2024 lead plaintiff deadline.
- 09/17/2024
|
Faruqi & Faruqi Reminds Lifecore Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 27, 2024 - LFCR
- Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Lifecore To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Lifecore between October 7, 2020 and March 19, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Sept.
- 09/17/2024
|
Lifecore Biomedical, Inc. Is Being Sued For Violating Securities Laws And Impacted Shareholders Should Lend A Hand To The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / September 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.
- 09/17/2024
|
LFCR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Lifecore Biomedical, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / September 17, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").
- 09/17/2024
|
LFCR DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Lifecore Biomedical, Inc. Investors to Secure Counsel Before Important September 27 Deadline in Securities Class Action – LFCR
- NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lifecore Biomedical, Inc. (NASDAQ: LFCR) between October 7, 2020 and March 19, 2024, both dates inclusive (the “Class Period”), of the important September 27, 2024 lead plaintiff deadline.
- 09/16/2024
|
LFCR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Lifecore Biomedical, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. (“Lifecore” or “the Company”) (NASDAQ: LFCR) and certain of its officers.
- 09/16/2024
|
A Securities Fraud Case Has Been Filed Against Lifecore Biomedical Inc And The Schall Law Firm Urges Investor Participation
- LOS ANGELES, CA / ACCESSWIRE / September 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.
- 09/16/2024
|
LFCR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Lifecore Biomedical, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / September 16, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").
- 09/16/2024
|
LFCR Investors Have Opportunity to Lead Lifecore Biomedical, Inc. Securities Fraud Lawsuit with the Schall Law Firm
- LOS ANGELES , Sept. 16, 2024 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ: LFCR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
- 09/16/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lifecore Biomedical, Inc. of Class Action Lawsuit and Upcoming Deadlines – LFCR
- NEW YORK, NY / ACCESSWIRE / September 15, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ:LFCR) and certain officers. The class action, filed in the United States District Court for the District of Minnesota, and docketed under 24-cv-03028, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 09/15/2024
|
Lifecore Biomedical, Inc. Is Being Sued For Possible Securities Law Violations And Affected Shareholders Are Invited To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / September 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.
- 09/15/2024
|
LFCR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Lifecore Biomedical, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / September 15, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").
- 09/15/2024
|
The Schall Law Firm Wants Investors With Losses In Lifecore Biomedical Inc To Contribute To A Lawsuit For Securities Fraud
- LOS ANGELES, CA / ACCESSWIRE / September 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.
- 09/14/2024
|
LFCR Investors Have Opportunity to Lead Lifecore Biomedical, Inc. Securities Fraud Lawsuit
- LOS ANGELES , Sept. 13, 2024 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ: LFCR).
- 09/13/2024
|
LFCR DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Lifecore Biomedical, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – LFCR
- NEW YORK, Sept. 13, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lifecore Biomedical, Inc. (NASDAQ: LFCR) between October 7, 2020 and March 19, 2024, both dates inclusive (the “Class Period”), of the important September 27, 2024 lead plaintiff deadline.
- 09/13/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lifecore Biomedical, Inc. of Class Action Lawsuit and Upcoming Deadlines - LFCR
- NEW YORK, NY / ACCESSWIRE / September 13, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ:LFCR) and certain officers. The class action, filed in the United States District Court for the District of Minnesota, and docketed under 24-cv-03028, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 09/13/2024
|
Lifecore Biomedical, Inc. May Have Violated Securities Laws And Shareholders Are Invited By The Schall Law Firm To Take Part In A Case
- LOS ANGELES, CA / ACCESSWIRE / September 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.
- 09/13/2024
|
LFCR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Lifecore Biomedical, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / September 13, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").
- 09/13/2024
|
Faruqi & Faruqi Reminds Lifecore Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 27, 2024 - LFCR
- Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Lifecore To Contact Him Directly To Discuss Their Options
- 09/13/2024
|
Lifecore Biomedical to Participate in Craig-Hallum Bioprocessing Conference
- CHASKA, Minn., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that Paul Josephs, the Company's president and chief executive officer, and Ryan Lake, the Company's chief financial officer, will be the featured speakers in a fireside chat at the upcoming Craig-Hallum Bioprocessing Conference. The conference will take place virtually on September 19, 2024.
- 09/12/2024
|
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Lifecore Biomedical, Inc. (LFCR)
- LOS ANGELES, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming September 27, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Lifecore Biomedical, Inc. (“Lifecore” or the “Company”) (NASDAQ: LFCR) securities between October 7, 2020 and March 19, 2024, inclusive (the “Class Period”).
- 09/12/2024
|
The Schall Law Firm Seeks Investor Participation In A Securities Fraud Lawsuit Against Lifecore Biomedical Inc
- LOS ANGELES, CA / ACCESSWIRE / September 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.
- 09/12/2024
|
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore
- Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Lifecore To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Lifecore between October 7, 2020 and March 19, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Sept.
- 09/12/2024
|
LFCR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Lifecore Biomedical, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / September 12, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").
- 09/12/2024
|
Lifecore Biomedical Regains Compliance with Nasdaq Listing Requirements
- CHASKA, Minn., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR ) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has received written notice from the Nasdaq Listing Qualifications Department stating that the Company has regained compliance with the filing requirement in Nasdaq Listing Rule 5250(c), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission, and that the Company has also cured the deficiency under Nasdaq Listing Rule 5620(a), which requires listed companies to hold an annual meeting of stockholders during each fiscal year. With the Company in compliance with Nasdaq Listing Rule 5250(c), and having cured its deficiency under Nasdaq Listing Rule 5620(a), Nasdaq has ceased any action to delist the Company's common stock.
- 09/12/2024
|
LFCR Investors Have Opportunity to Lead Lifecore Biomedical, Inc. Securities Fraud Lawsuit
- BENSALEM, Pa. , Sept. 11, 2024 /PRNewswire/ -- Law Offices of Howard G.
- 09/11/2024
|
Lead Plaintiff Deadline Quickly Approaching in Lifecore Biomedical, Inc. (LFCR) Class Action – Shareholders Should Contact Robbins LLP for Information
- Robbins LLP is Investigating Allegations that Lifecore Biomedical, Inc (LFCR) Misled Investors Regarding its Internal Controls Over Financial Reporting
- 09/11/2024
|
Lifecore Biomedical, Inc. Is Being Sued For Securities Law Violations And Shareholders Are Invited To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / September 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.
- 09/11/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lifecore Biomedical, Inc. of Class Action Lawsuit and Upcoming Deadlines - LFCR
- NEW YORK, NY / ACCESSWIRE / September 11, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ:LFCR) and certain officers. The class action, filed in the United States District Court for the District of Minnesota, and docketed under 24-cv-03028, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 09/11/2024
|
LFCR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Lifecore Biomedical, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / September 11, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").
- 09/11/2024
|
LFCR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Lifecore Biomedical, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- NEW YORK, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. (“Lifecore” or “the Company”) (NASDAQ: LFCR) and certain of its officers.
- 09/10/2024
|
The Schall Law Firm Urges Investor Participation In A Securities Fraud Case Against Lifecore Biomedical Inc
- LOS ANGELES, CA / ACCESSWIRE / September 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.
- 09/10/2024
|
LFCR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Lifecore Biomedical, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / September 10, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").
- 09/10/2024
|
Lifecore Biomedical Appoints Brikkelle Thompson as Senior Vice President of Human Resources
- Ms. Thompson Brings Nearly 25 Years of HR Leadership Driving Top Performing Cultures and Building Exceptional Teams Ms. Thompson Brings Nearly 25 Years of HR Leadership Driving Top Performing Cultures and Building Exceptional Teams
- 09/10/2024
|
Lifecore Biomedical, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. September 27, 2024 Deadline to file Lead Plaintiff Motion
- Investors can contact the law firm at no cost to learn more about recovering their losses
- 09/09/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lifecore Biomedical, Inc. of Class Action Lawsuit and Upcoming Deadlines - LFCR
- NEW YORK , Sept. 9, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ: LFCR) and certain officers.
- 09/09/2024
|
LFCR Investors Have Opportunity to Lead Lifecore Biomedical, Inc. Securities Fraud Lawsuit
- NEW YORK , Sept. 9, 2024 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lifecore Biomedical, Inc. (NASDAQ: LFCR) between October 7, 2020 and March 19, 2024, both dates inclusive (the "Class Period"), of the important September 27, 2024 lead plaintiff deadline.
- 09/09/2024
|
Lifecore Biomedical, Inc. Is Being Sued For Possibly Violating Securities Laws And Shareholders Are Invited To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / September 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.
- 09/09/2024
|
LFCR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Lifecore Biomedical, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / September 9, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").
- 09/09/2024
|
LFCR Investors Have Opportunity to Lead Lifecore Biomedical, Inc. Securities Fraud Lawsuit with the Schall Law Firm
- LOS ANGELES , Sept. 9, 2024 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ: LFCR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
- 09/09/2024
|
ROSEN, LEADING INVESTOR COUNSEL, Encourages Lifecore Biomedical, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – LFCR
- NEW YORK, Sept. 08, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lifecore Biomedical, Inc. (NASDAQ: LFCR) between October 7, 2020 and March 19, 2024, both dates inclusive (the “Class Period”), of the important September 27, 2024 lead plaintiff deadline.
- 09/08/2024
|
LFCR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Lifecore Biomedical, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / September 8, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").
- 09/08/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lifecore Biomedical, Inc. of Class Action Lawsuit and Upcoming Deadlines – LFCR
- NEW YORK, NY / ACCESSWIRE / September 7, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ:LFCR) and certain officers. The class action, filed in the United States District Court for the District of Minnesota, and docketed under 24-cv-03028, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 09/07/2024
|
The Schall Law Firm Urges Investor Participation In A Securities Fraud Lawsuit Against Lifecore Biomedical Inc
- LOS ANGELES, CA / ACCESSWIRE / September 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.
- 09/07/2024
|
LFCR Investors Have Opportunity to Lead Lifecore Biomedical, Inc. Securities Fraud Lawsuit
- LOS ANGELES , Sept. 6, 2024 /PRNewswire/ -- The Law Offices of Frank R.
- 09/06/2024
|
Lifecore Biomedical Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- CHASKA, Minn., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that Lifecore has granted a restricted stock unit (“RSU”) award with respect to 262,500 shares of its common stock and a performance stock unit (“PSU”) award for up to 750,000 shares of its common stock to Ryan D. Lake, Lifecore's newly hired chief financial officer. The RSU award and PSU award were granted September 3, 2024, pursuant to the Company's previously announced employment agreement with Mr. Lake, and as a material inducement to Mr. Lake joining Lifecore as chief financial officer.
- 09/06/2024
|
Lifecore Biomedical, Inc. May Have Committed Securities Related Infractions And Impacted Shareholders Are Invited To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / September 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.
- 09/06/2024
|
LFCR STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Lifecore Biomedical, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK CITY, NY / ACCESSWIRE / September 6, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").
- 09/06/2024
|
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Lifecore Biomedical, Inc. (LFCR)
- LOS ANGELES, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming September 27, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Lifecore Biomedical, Inc. (“Lifecore” or the “Company”) (NASDAQ: LFCR) securities between October 7, 2020 and March 19, 2024, inclusive (the “Class Period”).
- 09/05/2024
|
Lifecore Biomedical to Participate in 17th Annual Barrington Research Virtual Fall Investment Conference
- CHASKA, Minn., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the Company will participate in the upcoming 17th Annual Barrington Research Virtual Fall Investment Conference. Lifecore management will participate in 1-on-1 investor meetings during the event, which is scheduled to take place virtually on Thursday, September 12, 2024.
- 09/05/2024
|
The Schall Law Firm Seeks Investor Participation In A Lawsuit Against Lifecore Biomedical Inc For Securities Fraud
- LOS ANGELES, CA / ACCESSWIRE / September 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.
- 09/05/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lifecore Biomedical, Inc. of Class Action Lawsuit and Upcoming Deadlines - LFCR
- NEW YORK, NY / ACCESSWIRE / September 5, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ:LFCR) and certain officers. The class action, filed in the United States District Court for the District of Minnesota, and docketed under 24-cv-03028, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 09/05/2024
|
LFCR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of Lifecore Biomedical, Inc. to Contact the Firm Today!
- NEW YORK CITY, NY / ACCESSWIRE / September 5, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").
- 09/05/2024
|
LFCR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Lifecore Biomedical, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- NEW YORK, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. (“Lifecore” or “the Company”) (NASDAQ: LFCR) and certain of its officers.
- 09/04/2024
|
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Lifecore Biomedical, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – LFCR
- NEW YORK, Sept. 04, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lifecore Biomedical, Inc. (NASDAQ: LFCR) between October 7, 2020 and March 19, 2024, both dates inclusive (the “Class Period”), of the important September 27, 2024 lead plaintiff deadline.
- 09/04/2024
|
A Securities Fraud Lawsuit Has Been Filed On Behalf Of Investors In Lifecore Biomedical Inc And The Schall Law Firm Invites Investor Participation
- LOS ANGELES, CA / ACCESSWIRE / September 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.
- 09/04/2024
|
LFCR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of Lifecore Biomedical, Inc. to Contact the Firm Today!
- NEW YORK CITY, NY / ACCESSWIRE / September 4, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ: LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").
- 09/04/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lifecore Biomedical, Inc. of Class Action Lawsuit and Upcoming Deadlines - LFCR
- NEW YORK , Sept. 3, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ: LFCR) and certain officers.
- 09/03/2024
|
Lifecore Biomedical Inc. May Have Committed Securities Related Improprieties And Shareholders Are Urged To Contact The Schall Law Firm About A Case
- LOS ANGELES, CA / ACCESSWIRE / September 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.
- 09/03/2024
|
LFCR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Lifecore Biomedical, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK CITY, NY / ACCESSWIRE / September 3, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ: LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").
- 09/03/2024
|
LFCR Investors Have Opportunity to Lead Lifecore Biomedical, Inc. Securities Fraud Lawsuit with the Schall Law Firm
- LOS ANGELES , Sept. 3, 2024 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ: LFCR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
- 09/03/2024
|
LFCR Investors Have Opportunity to Lead Lifecore Biomedical, Inc. Securities Fraud Lawsuit
- NEW YORK , Sept. 2, 2024 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lifecore Biomedical, Inc. (NASDAQ: LFCR) between October 7, 2020 and March 19, 2024, both dates inclusive (the "Class Period"), of the important September 27, 2024 lead plaintiff deadline.
- 09/02/2024
|
The Schall Law Firm Wants Lifecore Biomedical Inc Investors To Play A Part In A Lawsuit For Securities Law Infractions
- LOS ANGELES, CA / ACCESSWIRE / September 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.
- 09/02/2024
|
LFCR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Lifecore Biomedical, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK CITY, NY / ACCESSWIRE / September 2, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ: LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").
- 09/02/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lifecore Biomedical, Inc. of Class Action Lawsuit and Upcoming Deadlines – LFCR
- NEW YORK, NY / ACCESSWIRE / September 1, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ:LFCR) and certain officers. The class action, filed in the United States District Court for the District of Minnesota, and docketed under 24-cv-03028, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 09/01/2024
|
A Case For Securities Fraud Has Been Filed Against Lifecore Biomedical Inc. And Stockholders With Losses Should Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / September 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.
- 09/01/2024
|
LFCR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Lifecore Biomedical, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK CITY, NY / ACCESSWIRE / September 1, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ: LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").
- 09/01/2024
|
Lifecore Biomedical Inc Is Being Sued For Violating Securities Regulations And The Schall Law Firm Wants Investors To Reach Out
- LOS ANGELES, CA / ACCESSWIRE / August 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.
- 08/31/2024
|
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore
- Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Lifecore To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Lifecore between October 7, 2020 and March 19, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Aug. 31, 2024 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ: LFCR) and reminds investors of the September 27, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
- 08/31/2024
|
LFCR Investors Have Opportunity to Lead Lifecore Biomedical, Inc. Securities Fraud Lawsuit
- LOS ANGELES , Aug. 30, 2024 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ: LFCR). Class Period: October 7, 2020 – March 19, 2024 Lead Plaintiff Deadline: September 27, 2024 If you wish to serve as lead plaintiff of the Lifecore lawsuit, you can submit your contact information at www.glancylaw.com/cases/Lifecore-Biomedical-Inc/.
- 08/30/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lifecore Biomedical, Inc. of Class Action Lawsuit and Upcoming Deadlines - LFCR
- NEW YORK, NY / ACCESSWIRE / August 30, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ:LFCR) and certain officers. The class action, filed in the United States District Court for the District of Minnesota, and docketed under 24-cv-03028, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 08/30/2024
|
Stakeholders In Lifecore Biomedical Inc. Are Urged By The Schall Law Firm To Play A Part In A Case For Securities Fraud
- LOS ANGELES, CA / ACCESSWIRE / August 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.
- 08/30/2024
|
LFCR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Lifecore Biomedical, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK CITY, NY / ACCESSWIRE / August 30, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").
- 08/30/2024
|
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore
- Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Lifecore To Contact Him Directly To Discuss Their Options
- 08/29/2024
|
LFCR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Lifecore Biomedical, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- NEW YORK, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. (“Lifecore” or “the Company”) (NASDAQ: LFCR) and certain of its officers.
- 08/29/2024
|
Lifecore Biomedical Inc. Is Being Sued For Possible Securities Law Infractions And The Schall Law Firm Invites Shareholder Participation
- LOS ANGELES, CA / ACCESSWIRE / August 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.
- 08/29/2024
|
LFCR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Lifecore Biomedical, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK CITY, NY / ACCESSWIRE / August 29, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ: LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").
- 08/29/2024
|
Lifecore Biomedical Announces Chief Financial Officer Transition
- Experienced CDMO Industry Financial Executive Ryan Lake Appointed CFO Experienced CDMO Industry Financial Executive Ryan Lake Appointed CFO
- 08/29/2024
|
Investors Are Encouraged By The Schall Law Firm To Participate In A Lawsuit Against Lifecore Biomedical Inc For Securities Fraud
- LOS ANGELES, CA / ACCESSWIRE / August 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.
- 08/28/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lifecore Biomedical, Inc. of Class Action Lawsuit and Upcoming Deadlines - LFCR
- NEW YORK, NY / ACCESSWIRE / August 28, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ:LFCR) and certain officers. The class action, filed in the United States District Court for the District of Minnesota, and docketed under 24-cv-03028, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 08/28/2024
|
LFCR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Lifecore Biomedical, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK CITY, NY / ACCESSWIRE / August 28, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ: LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").
- 08/28/2024
|
Lifecore (LFCR) Class Action Lawsuit Alert: Johnson Fistel Announces Shareholders with Substantial Losses Have the Opportunity to Lead the Action
- SAN DIEGO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ: LFCR).
- 08/28/2024
|
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Lifecore Biomedical, Inc. (LFCR)
- LOS ANGELES, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming September 27, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Lifecore Biomedical, Inc. (“Lifecore” or the “Company”) (NASDAQ: LFCR) securities between October 7, 2020 and March 19, 2024, inclusive (the “Class Period”).
- 08/27/2024
|
Lifecore Biomedical, Inc. (LFCR) Q4 2024 Earnings Conference Call Transcript
- Lifecore Biomedical, Inc. (NASDAQ:LFCR ) Q4 2024 Earnings Conference Call August 27, 2024 8:30 AM ET Company Participants Stephanie Diaz - Vida Strategic Partners, IR Paul Josephs - President & CEO John D. Morberg - CFO & EVP Conference Call Participants Michael Petusky - Barrington Research Operator Greetings, and welcome to the Lifecore Biomedical Q4 and Full Year 2024 Earnings Call.
- 08/27/2024
|
Lifecore Biomedical Inc Is Being Sued For Possible Securities Law Violations And The Schall Law Firm Invites Shareholders To Assist
- LOS ANGELES, CA / ACCESSWIRE / August 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.
- 08/27/2024
|
LFCR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Lifecore Biomedical, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK CITY, NY / ACCESSWIRE / August 27, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ: LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").
- 08/27/2024
|
ROSEN, LEADING INVESTOR COUNSEL, Encourages Lifecore Biomedical, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – LFCR
- NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lifecore Biomedical, Inc. (NASDAQ: LFCR) between October 7, 2020 and March 19, 2024, both dates inclusive (the “Class Period”), of the important September 27, 2024 lead plaintiff deadline.
- 08/26/2024
|
Lifecore Biomedical Reports Fourth Quarter and Fiscal Year End 2024 Financial Results and Provides Corporate Update
- -- Recorded Revenues of $128.3 million for Fiscal 2024; Year-Over-Year Increase of 24.2% -- -- High Value Pipeline Continues to Advance Toward Commercialization -- -- State-of-the-Art Technology Enhancements to Expand Capacity and New Business Opportunities –
- 08/26/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lifecore Biomedical, Inc. of Class Action Lawsuit and Upcoming Deadlines - LFCR
- NEW YORK , Aug. 26, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ: LFCR) and certain officers. The class action, filed in the United States District Court for the District of Minnesota, and docketed under 24-cv-03028, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 08/26/2024
|
The Schall Law Firm Is Seeking Investor Participation In A Securities Fraud Case Against Lifecore Biomedical Inc.
- LOS ANGELES, CA / ACCESSWIRE / August 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.
- 08/26/2024
|
LFCR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Lifecore Biomedical, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK CITY, NY / ACCESSWIRE / August 26, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ: LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").
- 08/26/2024
|
Kirby McInerney LLP Reminds Lifecore Biomedical, Inc. (LFCR) Investors of Class Action Filing and Encourages Investors to Contact the Firm
- NEW YORK--(BUSINESS WIRE)---- $LFCR--The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the District of Minnesota on behalf of those who acquired Lifecore Biomedical, Inc. (“Lifecore” or the “Company”) (NASDAQ: LFCR) securities during the period of October 7, 2020 to March 19, 2024, inclusive (“the Class Period”). Investors have until September 27, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit. [Cli.
- 08/26/2024
|
Lifecore Biomedical Inc. Is Being Sued For Potential Securities Law Infractions And The Schall Law Firm Invites Shareholder Involvement
- LOS ANGELES, CA / ACCESSWIRE / August 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.
- 08/25/2024
|
LFCR STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Lifecore Biomedical, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK CITY, NY / ACCESSWIRE / August 25, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ: LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").
- 08/25/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lifecore Biomedical, Inc. of Class Action Lawsuit and Upcoming Deadlines – LFCR
- NEW YORK, NY / ACCESSWIRE / August 24, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ:LFCR) and certain officers. The class action, filed in the United States District Court for the District of Minnesota, and docketed under 24-cv-03028, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 08/24/2024
|
A Case Against Lifecore Biomedical Inc For Securities Fraud Has Been Filed And The Schall Law Firm Seeks Investors To Reach Out
- LOS ANGELES, CA / ACCESSWIRE / August 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.
- 08/24/2024
|
LFCR Investors Have Opportunity to Lead Lifecore Biomedical, Inc. Securities Fraud Lawsuit
- NEW YORK , Aug. 24, 2024 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lifecore Biomedical, Inc. (NASDAQ: LFCR) between October 7, 2020 and March 19, 2024, both dates inclusive (the "Class Period"), of the important September 27, 2024 lead plaintiff deadline. So What: If you purchased Lifecore securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 08/24/2024
|
Pending Lead Plaintiff Deadline in the LFCR Class Action: Robbins LLP Reminds Stockholders With Large Losses of Lifecore Biomedical, Inc. to Seek Counsel
- Robbins LLP is Investigating Allegations that Lifecore Biomedical, Inc (LFCR) Misled Investors Regarding its Internal Controls Over Financial Reporting
- 08/23/2024
|
LFCR Investors Have Opportunity to Lead Lifecore Biomedical, Inc. Securities Fraud Lawsuit
- LOS ANGELES , Aug. 23, 2024 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ: LFCR).
- 08/23/2024
|
LFCR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Lifecore Biomedical, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- NEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. (“Lifecore” or “the Company”) (NASDAQ: LFCR) and certain of its officers.
- 08/23/2024
|
Lifecore Biomedical Inc Is Being Sued By The Schall Law Firm For Violations Of Securities Regulations And Stockholders Are Urged To Sign Up
- LOS ANGELES, CA / ACCESSWIRE / August 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.
- 08/23/2024
|
LFCR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Lifecore Biomedical, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / August 23, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").
- 08/23/2024
|
ROSEN, LEADING INVESTOR COUNSEL, Encourages Lifecore Biomedical, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – LFCR
- NEW YORK, Aug. 22, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lifecore Biomedical, Inc. (NASDAQ: LFCR) between October 7, 2020 and March 19, 2024, both dates inclusive (the “Class Period”), of the important September 27, 2024 lead plaintiff deadline.
- 08/22/2024
|
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore
- Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Lifecore To Contact Him Directly To Discuss Their Options
- 08/22/2024
|
Lifecore Biomedical Inc Investors Are Invited By The Schall Law Firm To Participate In A Securities Fraud Lawsuit
- LOS ANGELES, CA / ACCESSWIRE / August 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.
- 08/22/2024
|
LFCR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Lifecore Biomedical, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / August 22, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").
- 08/22/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lifecore Biomedical, Inc. of Class Action Lawsuit and Upcoming Deadlines - LFCR
- NEW YORK, NY / ACCESSWIRE / August 22, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ:LFCR) and certain officers. The class action, filed in the United States District Court for the District of Minnesota, and docketed under 24-cv-03028, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 08/22/2024
|
Shareholders With Losses In Lifecore Biomedical Inc Are Encouraged To Join The Schall Law Firm In A Securities Fraud Suit
- LOS ANGELES, CA / ACCESSWIRE / August 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.
- 08/21/2024
|
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore
- Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Lifecore To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Lifecore between October 7, 2020 and March 19, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Aug. 21, 2024 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ: LFCR) and reminds investors of the September 27, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
- 08/21/2024
|
LFCR Investors Have Opportunity to Lead Lifecore Biomedical, Inc. Securities Fraud Lawsuit with the Schall Law Firm
- LOS ANGELES, Aug. 21, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. (“Lifecore” or “the Company”) (NASDAQ: LFCR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the “Class Period”), are encouraged to contact the firm before September 27, 2024.
- 08/21/2024
|
LFCR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Lifecore Biomedical, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / August 21, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").
- 08/21/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lifecore Biomedical, Inc. of Class Action Lawsuit and Upcoming Deadlines – LFCR
- NEW YORK, NY / ACCESSWIRE / August 21, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ:LFCR) and certain officers. The class action, filed in the United States District Court for the District of Minnesota, and docketed under 24-cv-03028, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 08/21/2024
|
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Lifecore Biomedical, Inc. (LFCR)
- LOS ANGELES, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming September 27, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Lifecore Biomedical, Inc. (“Lifecore” or the “Company”) (NASDAQ: LFCR) securities between October 7, 2020 and March 19, 2024, inclusive (the “Class Period”).
- 08/20/2024
|
The Schall Law Firm Invites Investors To Join In The Securities Fraud Lawsuit Of Lifecore Biomedical Inc Before Sep 27, 2024
- LOS ANGELES, CA / ACCESSWIRE / August 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.
- 08/20/2024
|
LFCR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Lifecore Biomedical, Inc. Investors Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / August 20, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").
- 08/20/2024
|
The Schall Law Firm Encourages Stockholders To Participate In The Lifecore Biomedical Inc Securities Fraud Lawsuit
- LOS ANGELES, CA / ACCESSWIRE / August 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.
- 08/19/2024
|
LFCR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Lifecore Biomedical, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / August 19, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").
- 08/19/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lifecore Biomedical, Inc. of Class Action Lawsuit and Upcoming Deadlines – LFCR
- NEW YORK, NY / ACCESSWIRE / August 19, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ: LFCR) and certain officers. The class action, filed in the United States District Court for the District of Minnesota, and docketed under 24-cv-03028, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 08/19/2024
|
Shareholder Rights Law Firm Robbins LLP Urges LFCR Stockholders to Contact the Firm for Information About the Lifecore Biomedical, Inc. Class Action
- Robbins LLP is Investigating Allegations that Lifecore Biomedical, Inc (LFCR) Misled Investors Regarding its Internal Controls Over Financial Reporting
- 08/19/2024
|
LFCR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Lifecore Biomedical, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- NEW YORK, Aug. 18, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. (“Lifecore” or “the Company”) (NASDAQ: LFCR) and certain of its officers.
- 08/18/2024
|
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Lifecore Biomedical, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – LFCR
- NEW YORK, Aug. 18, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lifecore Biomedical, Inc. (NASDAQ: LFCR) between October 7, 2020 and March 19, 2024, both dates inclusive (the “Class Period”), of the important September 27, 2024 lead plaintiff deadline.
- 08/18/2024
|
The Schall Law Firm Urges Investors To Join The Lifecore Biomedical Inc Securities Fraud Lawsuit
- LOS ANGELES, CA / ACCESSWIRE / August 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.
- 08/18/2024
|
LFCR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Lifecore Biomedical, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / August 18, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").
- 08/18/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lifecore Biomedical, Inc. of Class Action Lawsuit and Upcoming Deadlines - LFCR
- NEW YORK , Aug. 17, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ: LFCR) and certain officers. The class action, filed in the United States District Court for the District of Minnesota, and docketed under 24-cv-03028, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 08/17/2024
|
LFCR Investors Have Opportunity to Lead Lifecore Biomedical, Inc. Securities Fraud Lawsuit
- NEW YORK , Aug. 16, 2024 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lifecore Biomedical, Inc. (NASDAQ: LFCR) between October 7, 2020 and March 19, 2024, both dates inclusive (the "Class Period"), of the important September 27, 2024 lead plaintiff deadline. So What: If you purchased Lifecore securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 08/16/2024
|
LFCR Investors Have Opportunity to Lead Lifecore Biomedical, Inc. Securities Fraud Lawsuit
- LOS ANGELES , Aug. 16, 2024 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ: LFCR). Class Period: October 7, 2020 – March 19, 2024 Lead Plaintiff Deadline: September 27, 2024 If you wish to serve as lead plaintiff of the Lifecore lawsuit, you can submit your contact information at www.glancylaw.com/cases/Lifecore-Biomedical-Inc/.
- 08/16/2024
|
The Schall Law Firm Seeks Investors To Take The Lead In The Lifecore Biomedical Inc Securities Fraud Lawsuit
- LOS ANGELES, CA / ACCESSWIRE / August 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.
- 08/16/2024
|
LFCR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Lifecore Biomedical, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / August 16, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").
- 08/16/2024
|
The Schall Law Firm Wants Investors To Take The Lead In The Lifecore Biomedical Inc Securities Fraud Lawsuit
- LOS ANGELES, CA / ACCESSWIRE / August 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.
- 08/15/2024
|
LFCR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Lifecore Biomedical, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / August 15, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").
- 08/15/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lifecore Biomedical, Inc. of Class Action Lawsuit and Upcoming Deadlines - LFCR
- NEW YORK, NY / ACCESSWIRE / August 15, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ:LFCR) and certain officers. The class action, filed in the United States District Court for the District of Minnesota, and docketed under 24-cv-03028, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 08/15/2024
|
The Schall Law Firm Encourages Investors To Take The Lead In The Lifecore Biomedical Inc Securities Fraud Lawsuit
- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.
- 08/14/2024
|
ROSEN, A LEADING NATIONAL FIRM, Encourages Lifecore Biomedical, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – LFCR
- NEW YORK, Aug. 14, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lifecore Biomedical, Inc. (NASDAQ: LFCR) between October 7, 2020 and March 19, 2024, both dates inclusive (the “Class Period”), of the important September 27, 2024 lead plaintiff deadline.
- 08/14/2024
|
LFCR Investors Have Opportunity to Lead Lifecore Biomedical, Inc. Securities Fraud Lawsuit
- BENSALEM, Pa. , Aug. 14, 2024 /PRNewswire/ -- Law Offices of Howard G.
- 08/14/2024
|
LFCR Investors Have Opportunity to Lead Lifecore Biomedical, Inc. Securities Fraud Lawsuit with the Schall Law Firm
- LOS ANGELES, Aug. 14, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. (“Lifecore” or “the Company”) (NASDAQ: LFCR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the “Class Period”), are encouraged to contact the firm before September 27, 2024.
- 08/14/2024
|
LFCR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Lifecore Biomedical, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / August 14, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").
- 08/14/2024
|
The Schall Law Firm Invites Investors To Lead The Lifecore Biomedical Inc Securities Fraud Lawsuit
- LOS ANGELES, CA / ACCESSWIRE / August 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.
- 08/14/2024
|
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Lifecore Biomedical, Inc. (LFCR)
- LOS ANGELES, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming September 27, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Lifecore Biomedical, Inc. (“Lifecore” or the “Company”) (NASDAQ: LFCR) securities between October 7, 2020 and March 19, 2024, inclusive (the “Class Period”).
- 08/13/2024
|
LFCR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Lifecore Biomedical, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / August 13, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").
- 08/13/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lifecore Biomedical, Inc. of Class Action Lawsuit and Upcoming Deadlines - LFCR
- NEW YORK, NY / ACCESSWIRE / August 13, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ:LFCR) and certain officers. The class action, filed in the United States District Court for the District of Minnesota, and docketed under 24-cv-03028, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 08/13/2024
|
Investors May Lead The Securities Fraud Lawsuit Against Lifecore Biomedical Inc With The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / August 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.
- 08/12/2024
|
LFCR CLASS ACTION ALERT: Robbins LLP Reminds Stockholders of the Lead Plaintiff Deadline in the Lifecore Biomedical, Inc. Class Action
- Robbins LLP is Investigating Allegations that Lifecore Biomedical, Inc (LFCR) Misled Investors Regarding its Internal Controls Over Financial Reporting
- 08/12/2024
|
LFCR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Lifecore Biomedical, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- NEW YORK, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. (“Lifecore” or “the Company”) (NASDAQ: LFCR) and certain of its officers.
- 08/12/2024
|
LFCR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Lifecore Biomedical, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / August 12, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").
- 08/12/2024
|
LFCR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Lifecore Biomedical, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK , Aug. 11, 2024 /PRNewswire/ -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ: LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").
- 08/11/2024
|
LFCR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Lifecore Biomedical, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / August 11, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").
- 08/11/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lifecore Biomedical, Inc. of Class Action Lawsuit and Upcoming Deadlines – LFCR
- NEW YORK, NY / ACCESSWIRE / August 11, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ:LFCR) and certain officers. The class action, filed in the United States District Court for the District of Minnesota, and docketed under 24-cv-03028, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 08/11/2024
|
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Lifecore Biomedical, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – LFCR
- NEW YORK, Aug. 09, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lifecore Biomedical, Inc. (NASDAQ: LFCR) between October 7, 2020 and March 19, 2024, both dates inclusive (the “Class Period”), of the important September 27, 2024 lead plaintiff deadline.
- 08/09/2024
|
Investors Can Lead The Lifecore Biomedical Inc Securities Fraud Lawsuit With The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / August 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.
- 08/09/2024
|
Poulin I Willey I Anastopoulo Announces A Class Action Lawsuit Has Been Filed Against Lifecore Biomedical, Inc. (LFCR)
- Poulin Willey Anastopoulo LLC announces that a class action has been filed in the United States District Court for the District of Minnesota on behalf of all persons and entities that purchased or otherwise acquired (or owned) the securities of Lifecore Biomedical, Inc. (“LFCR” or the “Company”) (NASDAQ:LFCR) between October 7, 2020, and March 19, 2024, both dates inclusive (the “Class Period”). The Company, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the U.S. and internationally, purportedly designing, developing, manufacturing, and selling differentiated products for biomaterials markets, and license technology applications to partners. Poulin Willey Anastopoulo LLC announces that a class action has been filed in the United States District Court for the District of Minnesota on behalf of all persons and entities that purchased or otherwise acquired (or owned) the securities of Lifecore Biomedical, Inc. (“LFCR” or the “Company”) (NASDAQ:LFCR) between October 7, 2020, and March 19, 2024, both dates inclusive (the “Class Period”). The Company, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the U.S. and internationally, purportedly designing, developing, manufacturing, and selling differentiated products for biomaterials markets, and license technology applications to partners.
- 08/09/2024
|
LFCR Investors Have Opportunity to Lead Lifecore Biomedical, Inc. Securities Fraud Lawsuit
- LOS ANGELES , Aug. 9, 2024 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ: LFCR).
- 08/09/2024
|
LFCR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Lifecore Biomedical, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK CITY, NY / ACCESSWIRE / August 9, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").
- 08/09/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lifecore Biomedical, Inc. of Class Action Lawsuit and Upcoming Deadlines - LFCR
- NEW YORK, Aug. 9, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ: LFCR) and certain officers. The class action, filed in the United States District Court for the District of Minnesota, and docketed under 24-cv-03028, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 08/09/2024
|
Kirby McInerney LLP Reminds Lifecore Biomedical, Inc. (LFCR) Investors of Class Action Filing and Encourages Investors to Contact the Firm
- NEW YORK, Aug. 09, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the District of Minnesota on behalf of those who acquired Lifecore Biomedical, Inc. (“Lifecore” or the “Company”) (NASDAQ: LFCR) securities during the period of October 7, 2020 to March 19, 2024, inclusive (“the Class Period”). Investors have until September 27, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
- 08/09/2024
|
Investors Can Take The Lead In The Lifecore Biomedical Inc Securities Fraud Lawsuit With The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / August 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.
- 08/08/2024
|
LFCR Investors Have Opportunity to Lead Lifecore Biomedical, Inc. Securities Fraud Lawsuit
- NEW YORK , Aug. 8, 2024 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lifecore Biomedical, Inc. (NASDAQ: LFCR) between October 7, 2020 and March 19, 2024, both dates inclusive (the "Class Period"), of the important September 27, 2024 lead plaintiff deadline. So What: If you purchased Lifecore securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 08/08/2024
|
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore
- Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Lifecore To Contact Him Directly To Discuss Their Options
- 08/08/2024
|
LFCR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Lifecore Biomedical, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK CITY, NY / ACCESSWIRE / August 8, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").
- 08/08/2024
|
LFCR Investors Can Take The Lead In The Lifecore Biomedical Inc Securities Fraud Lawsuit With The Schall Law Firm
- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.
- 08/07/2024
|
Shareholder Alert: Robbins LLP Informs Investors of the Class Action Filed Against Lifecore Biomedical, Inc. (LFCR)
- Robbins LLP is Investigating Allegations that Lifecore Biomedical, Inc (LFCR) Misled Investors Regarding its Internal Controls Over Financial Reporting
- 08/07/2024
|
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Lifecore Biomedical, Inc. (LFCR)
- LOS ANGELES, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming September 27, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Lifecore Biomedical, Inc. (“Lifecore” or the “Company”) (NASDAQ: LFCR) securities between October 7, 2020 and March 19, 2024, inclusive (the “Class Period”).
- 08/07/2024
|
Lifecore (LFCR) Class Action Lawsuit Alert: Johnson Fistel Announces Shareholders with Substantial Losses Have the Opportunity to Lead the Action
- SAN DIEGO , Aug. 7, 2024 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ: LFCR). If you incurred significant losses and want to act as the lead plaintiff in the Lifecore class action lawsuit or determine if you are eligible to receive a potential recovery of your losses, please submit your details here: SUBMIT YOUR INFORMATION NOW CLASS PERIOD: October 7, 2020 to March 19, 2024 LEAD PLAINTIFF DEADLINE: September 27, 2024 DOCKET #: 0:24cv03028 (D.
- 08/07/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lifecore Biomedical, Inc. of Class Action Lawsuit and Upcoming Deadlines - LFCR
- NEW YORK, NY / ACCESSWIRE / August 7, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ:LFCR) and certain officers. The class action, filed in the United States District Court for the District of Minnesota, and docketed under 24-cv-03028, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 08/07/2024
|
LFCR Investors Have Opportunity to Lead Lifecore Biomedical, Inc. Securities Fraud Lawsuit with the Schall Law Firm
- LOS ANGELES, Aug. 07, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. (“Lifecore” or “the Company”) (NASDAQ: LFCR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the “Class Period”), are encouraged to contact the firm before September 27, 2024.
- 08/07/2024
|
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore
- Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Lifecore To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Lifecore between October 7, 2020 and March 19, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/LFCR.
- 08/07/2024
|
LFCR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Lifecore Biomedical, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK CITY, NY / ACCESSWIRE / August 7, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").
- 08/07/2024
|
LFCR Investors Have Opportunity To Lead Lifecore Biomedical Inc Securities Fraud Lawsuit With The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / August 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.
- 08/06/2024
|
LFCR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Lifecore Biomedical, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. (“Lifecore” or “the Company”) (NASDAQ: LFCR) and certain of its officers.
- 08/06/2024
|
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Lifecore Biomedical, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – LFCR
- NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Lifecore Biomedical, Inc. (NASDAQ: LFCR) between October 7, 2020 and March 19, 2024, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 27, 2024.
- 08/06/2024
|
LFCR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Lifecore Biomedical, Inc. Investors Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK CITY, NY / ACCESSWIRE / August 6, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").
- 08/06/2024
|
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Lifecore Biomedical, Inc. (LFCR)
- LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming September 27, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Lifecore Biomedical, Inc. (“Lifecore” or the “Company”) (NASDAQ: LFCR) securities between October 7, 2020 and March 19, 2024, inclusive (the “Class Period”). If you suffered a loss on your Lifecore investments or would like to inquire about potential.
- 08/05/2024
|
LFCR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Lifecore Biomedical, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK CITY, NY / ACCESSWIRE / August 5, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").
- 08/05/2024
|
LFCR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Lifecore Biomedical, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK--(BUSINESS WIRE)---- $LFCR #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. (“Lifecore” or “the Company”) (NASDAQ: LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lif.
- 08/04/2024
|
LFCR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Lifecore Biomedical, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK CITY, NY / ACCESSWIRE / August 4, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").
- 08/04/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lifecore Biomedical, Inc. of Class Action Lawsuit and Upcoming Deadlines – LFCR
- NEW YORK, Aug. 03, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Lifecore Biomedical, Inc. (“Lifecore” or the “Company”) (NASDAQ: LFCR) and certain officers. The class action, filed in the United States District Court for the District of Minnesota, and docketed under 24-cv-03028, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 08/03/2024
|
Lifecore (LFCR) Class Action Lawsuit Alert: Johnson Fistel Announces Shareholders with Substantial Losses Have the Opportunity to Lead the Action
- SAN DIEGO, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ: LFCR).
- 08/02/2024
|
LFCR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Lifecore Biomedical, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK , Aug. 2, 2024 /PRNewswire/ -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ: LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").
- 08/02/2024
|
ROSEN, LEADING INVESTOR COUNSEL, Encourages Lifecore Biomedical, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – LFCR
- NEW YORK, Aug. 02, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of all purchasers of securities of Lifecore Biomedical, Inc. (NASDAQ: LFCR) between October 7, 2020 and March 19, 2024. Lifecore describes itself as an “integrated contract development and manufacturing organization in the U.S. and internationally.” A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 27, 2024.
- 08/02/2024
|
LFCR STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Lifecore Biomedical, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / August 2, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").
- 08/02/2024
|
Lifecore Biomedical, Inc. Class Action Alert: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the District of Minnesota against Lifecore Biomedical, Inc.
- Upcoming Lead Plaintiff Deadline is September 27, 2024 NEW YORK , Aug. 2, 2024 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein") announces that a federal securities class action lawsuit has been filed in the United States District Court for the District of Minnesota on behalf of those who acquired Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ: LFCR) securities during the period of October 7, 2020 to March 19,2024, inclusive ("the Class Period"). A ll investors who purchased shares and incurred losses are advised to contact the firm immediately at classmember@whafh.com or (800) 575-0735 or (212) 545-4774.
- 08/02/2024
|
Lifecore Biomedical, Inc Sued for Securities Law Violations - Contact The Rosen Law Firm Before September 27, 2024 to Discuss Your Rights - LFCR
- NEW YORK , Aug. 1, 2024 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of all purchasers of securities of Lifecore Biomedical, Inc. (NASDAQ: LFCR) between October 7, 2020 and March 19, 2024. Lifecore describes itself as an "integrated contract development and manufacturing organization in the U.S. and internationally.
- 08/01/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lifecore Biomedical, Inc. of Class Action Lawsuit and Upcoming Deadlines - LFCR
- NEW YORK , Aug. 1, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ: LFCR) and certain officers. The class action, filed in the United States District Court for the District of Minnesota, and docketed under 24-cv-03028, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 08/01/2024
|
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Lifecore Biomedical, Inc. (LFCR) Investors
- LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Lifecore Biomedical, Inc. (LFCR) Investors.
- 08/01/2024
|
LFCR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Lifecore Biomedical, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK CITY, NY / ACCESSWIRE / August 1, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").
- 08/01/2024
|
LFCR Investors Have Opportunity to Lead Lifecore Biomedical, Inc. Securities Fraud Lawsuit with the Schall Law Firm
- LOS ANGELES , Aug. 1, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ: LFCR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.
- 08/01/2024
|
LFCR INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Lifecore Biomedical, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Lifecore Biomedical, Inc. (NASDAQ: LFCR) securities between October 7, 2020 and March 19, 2024, both dates inclusive (the “Class Period”), have until September 27, 2024 to seek appointment as lead plaintiff of the Lifecore Biomedical class action lawsuit. Captioned Carew v. Lifecore Biomedical, Inc., No. 24-cv-03028 (D. Minn.), the Lifecore Biomedical class action lawsuit charges Lifecore Biomedical and certain of Lifecore Biomedical's top current and former executives with violations of the Securities Exchange Act of 1934.
- 08/01/2024
|
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Lifecore Biomedical, Inc. (LFCR) Investors
- LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Lifecore Biomedical, Inc. (“Lifecore” or the “Company”) (NASDAQ: LFCR) securities between October 7, 2020 and March 19, 2024, inclusive (the “Class Period”). Lifecore investors have until September 27, 2024 to file a lead plaintiff motion. If you suffered a loss on yo.
- 07/31/2024
|
LIFECORE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Lifecore Biomedical, Inc. and Encourages Investors to Contact the Firm
- NEW YORK, July 31, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Lifecore Biomedical, Inc. (“Lifecore” or the “Company”) (NASDAQ: LFCR) in the United States District Court for the District of Minnesota on behalf of all persons and entities who purchased or otherwise acquired Lifecore securities between October 7, 2020 and March 19, 2024, both dates inclusive (the “Class Period”). Investors have until September 27, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
- 07/31/2024
|
LIFECORE BIOMEDICAL, INC. (NASDAQ: LFCR) INVESTOR ALERT: Investors With Large Losses in Lifecore Biomedical Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
- LIFECORE BIOMEDICAL, INC. (NASDAQ: LFCR) INVESTOR ALERT: Investors With Large Losses in Lifecore Biomedical Inc. Should Contact Bernstein Liebhard LLP
- 07/31/2024
|
LFCR Investors Have Opportunity to Lead Lifecore Biomedical, Inc. Securities Fraud Lawsuit with the Schall Law Firm
- LOS ANGELES, July 31, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. (“Lifecore” or “the Company”) (NASDAQ: LFCR ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the “Class Period”), are encouraged to contact the firm before September 27, 2024.
- 07/31/2024
|
LFCR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Lifecore Biomedical, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK CITY, NY / ACCESSWIRE / July 31, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").
- 07/31/2024
|
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore
- Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Lifecore To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Lifecore between October 7, 2020 and March 19, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/LFCR.
- 07/31/2024
|
LFCR INVESTOR NOTICE: Lifecore Biomedical, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- SAN DIEGO, CA / ACCESSWIRE / July 31, 2024 / The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Lifecore Biomedical, Inc. (NASDAQ:LFCR) securities between October 7, 2020 and March 19, 2024, both dates inclusive (the "Class Period"), have until September 27, 2024 to seek appointment as lead plaintiff of the Lifecore Biomedical class action lawsuit. Captioned Carew v.
- 07/31/2024
|
Lifecore Biomedical Inc Is Being Investigated By The Schall Law Firm Which Urges Investors With Losses To Start A Conversation
- LOS ANGELES, CA / ACCESSWIRE / July 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/31/2024
|
LFCR Investors Have Opportunity to Lead Lifecore Biomedical, Inc. Securities Fraud Lawsuit with the Schall Law Firm
- LOS ANGELES--(BUSINESS WIRE)--LFCR Investors Have Opportunity to Lead Lifecore Biomedical, Inc. Securities Fraud Lawsuit with the Schall Law Firm.
- 07/30/2024
|
LFCR INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Lifecore Biomedical, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- SAN DIEGO--(BUSINESS WIRE)--The suit alleges defendants issued false statements concerning Lifecore business and prospects, resulting in its stock trading at inflated prices.
- 07/30/2024
|
SHAREHOLDER ALERT: Class Action Lawsuit Filed on Behalf of Lifecore Biomedical, Inc. (LFCR) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm
- ATLANTA, July 30, 2024 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Lifecore Biomedical, Inc. (“LifeCore” or the “Company”) (NASDAQ: LFCR). The lawsuit alleges that Defendants made materially false and misleading statements and/or failed to disclose adverse information regarding the Company's business, operations, and prospects, including allegations that: (i) Lifecore maintained deficient internal controls over financial reporting; (ii) as a result, the Company issued several financial statements that were inaccurate and would need to be restated; (iii) Lifecore's purported remediation efforts with respect to the foregoing deficiencies were ineffective; (iv) all of the foregoing impaired Lifecore's ability to timely file periodic reports with the SEC in compliance with NASDAQ listing requirements; and (v) accordingly, the Company's financial position and/or prospects were materially overstated.
- 07/30/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lifecore Biomedical, Inc. of Class Action Lawsuit and Upcoming Deadlines - LFCR
- NEW YORK, NY / ACCESSWIRE / July 30, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ:LFCR) and certain officers. The class action, filed in the United States District Court for the District of Minnesota, and docketed under 24-cv-03028, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 07/30/2024
|
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Lifecore Biomedical, Inc. (LFCR)
- NEW YORK, July 30, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the District of Minnesota on behalf of all persons or entities who purchased or otherwise acquired Lifecore Biomedical, Inc. (“Lifecore” or the “Company”) (NASDAQ: LFCR) securities between October 7, 2020 and March 19, 2024, inclusive (the “Class Period”). The lawsuit seeks to recover damages for the Company's investors under the federal securities laws.
- 07/30/2024
|
Lifecore Biomedical Inc Is Under Scrutiny By The Schall Law Firm Which Encourages Investors With Losses To Initiate Dialogue
- LOS ANGELES, CA / ACCESSWIRE / July 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/30/2024
|
Lifecore Biomedical Inc Is Under Scrutiny By The Schall Law Firm Which Encourages Investors With Losses To Initiate Dialogue
- LOS ANGELES, CA / ACCESSWIRE / July 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/29/2024
|
LFCR INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Lifecore Biomedical, Inc. Investors with Substantial Losses Have Opportunity to Lead the Lifecore Biomedical Class Action Lawsuit
- SAN DIEGO, July 29, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that the Lifecore Biomedical class action lawsuit seeks to represent purchasers or acquirers of Lifecore Biomedical, Inc. (NASDAQ: LFCR) securities between October 7, 2020 and March 19, 2024, inclusive (the “Class Period”). Captioned Carew v. Lifecore Biomedical, Inc., No. 24-cv-03028 (D. Minn.), the Lifecore Biomedical class action lawsuit charges Lifecore Biomedical and certain of Lifecore Biomedical's top current and former executives with violations of the Securities Exchange Act of 1934.
- 07/29/2024
|
Lifecore Biomedical Inc Under Scrutiny By The Schall Law Firm Encourages Investors With Losses To Begin Dialogue
- LOS ANGELES, CA / ACCESSWIRE / July 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/26/2024
|
Lifecore Biomedical Inc Under Scrutiny By The Schall Law Firm Encourages Investors With Losses To Begin Dialogue
- LOS ANGELES, CA / ACCESSWIRE / July 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/25/2024
|
Lifecore Biomedical Inc Under Scrutiny By The Schall Law Firm Encourages Investors With Losses To Begin Dialogue
- LOS ANGELES, CA / ACCESSWIRE / July 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/24/2024
|
Lifecore Biomedical Inc Under Scrutiny By The Schall Law Firm Encourages Investors With Losses To Begin Dialogue
- LOS ANGELES, CA / ACCESSWIRE / July 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/23/2024
|
Lifecore Biomedical Inc Under Scrutiny By The Schall Law Firm Encourages Investors With Losses To Begin Dialogue
- LOS ANGELES, CA / ACCESSWIRE / July 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/22/2024
|
The Schall Law Firm Is Conducting An Examination Into Lifecore Biomedical Incorporated And Encourages Investors With Losses To Begin Dialogue
- LOS ANGELES, CA / ACCESSWIRE / July 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/19/2024
|
Lifecore Biomedical, Inc. (LFCR) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates
- NEW YORK, NY / ACCESSWIRE / July 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Lifecore Biomedical, Inc. ("Lifecore") (NASDAQ:LFCR) concerning possible violations of federal securities laws. Lifecore announced on March 20, 2024, that its Board of Directors had concluded its review of strategic alternatives, in which it "unanimously concluded that the best way to maximize value for stockholders at this time is to continue executing on the Company's standalone strategic plan.
- 07/19/2024
|
Lifecore Biomedical Incorporated Is Being Examined By The Schall Law Firm Urging Investors With Losses To Initiate Conversation
- LOS ANGELES, CA / ACCESSWIRE / July 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/18/2024
|
Lifecore Biomedical Inc Is Under Scrutiny By The Schall Law Firm, Investors With Losses Are Encouraged To Initiate Dialogues
- LOS ANGELES, CA / ACCESSWIRE / July 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/17/2024
|
The Schall Law Firm Urges Investors With Losses To Start Conversations, Lifecore Biomedical Inc Under Investigation
- LOS ANGELES, CA / ACCESSWIRE / July 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/16/2024
|
Lifecore Biomedical Inc Under Scrutiny By The Schall Law Firm Encouraging Investors With Losses To Begin Dialogue
- LOS ANGELES, CA / ACCESSWIRE / July 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/15/2024
|
The Schall Law Firm Has Begun A Probe Into Lifecore Biomedical Inc And Encourages Investors With Losses To Initiate Conversation
- LOS ANGELES, CA / ACCESSWIRE / July 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/13/2024
|
Investigation Into Lifecore Biomedical Inc Commenced By The Schall Law Firm Inviting Investors With Losses To Start Dialogue
- LOS ANGELES, CA / ACCESSWIRE / July 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/12/2024
|
Lifecore Biomedical Inc Under Investigation By The Schall Law Firm Urging Investors With Losses To Initiate Conversation
- LOS ANGELES, CA / ACCESSWIRE / July 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/11/2024
|
The Schall Law Firm Begins Inquiry Into Lifecore Biomedical Inc And Encourages Investors With Losses To Start Dialogue
- LOS ANGELES, CA / ACCESSWIRE / July 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/10/2024
|
The Schall Law Firm Starts Investigation Into Lifecore Biomedical Inc And Urges Investors With Losses To Initiate Conversation
- LOS ANGELES, CA / ACCESSWIRE / July 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/09/2024
|
The Schall Law Firm Initiates Probe Into Lifecore Biomedical Inc And Encourages Investors With Losses To Engage In Dialogue
- LOS ANGELES, CA / ACCESSWIRE / July 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/08/2024
|
The Schall Law Firm Promotes Contact From Investors With Losses As It Embarks On Examination Of Lifecore Biomedical Inc
- LOS ANGELES, CA / ACCESSWIRE / July 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/07/2024
|
Investigation Into Lifecore Biomedical Inc Begins By The Schall Law Firm And It Urges Investors With Losses To Start Communication
- LOS ANGELES, CA / ACCESSWIRE / July 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/06/2024
|
The Schall Law Firm Motivates Investors With Losses To Initiate Interaction As It Commences Inquiry Into Lifecore Biomedical Inc
- LOS ANGELES, CA / ACCESSWIRE / July 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/05/2024
|
The Schall Law Firm Urges Investors With Losses To Initiate Communication As It Begins Inquiry Into Lifecore Biomedical Inc
- LOS ANGELES, CA / ACCESSWIRE / July 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/03/2024
|
The Schall Law Firm Encourages Investors With Losses To Begin Contact As It Starts Investigation Into Lifecore Biomedical Inc
- LOS ANGELES, CA / ACCESSWIRE / July 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/02/2024
|
The Schall Law Firm Urges Investors With Losses To Initiate Contact As It Commences Probe Into Lifecore Biomedical Inc.
- LOS ANGELES, CA / ACCESSWIRE / June 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/28/2024
|
The Schall Law Firm Encourages Investors With Losses To Establish Communication As It Begins Investigation Into Lifecore Biomedical Inc
- LOS ANGELES, CA / ACCESSWIRE / June 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/26/2024
|
The Schall Law Firm Urges Investors With Losses To Initiate Contact As It Commences Probe Into Lifecore Biomedical Inc
- LOS ANGELES, CA / ACCESSWIRE / June 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/25/2024
|
The Schall Law Firm Encourages Investors With Losses To Establish Communication As It Begins Investigation Into Lifecore Biomedical Inc
- LOS ANGELES, CA / ACCESSWIRE / June 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/24/2024
|
The Schall Law Firm Urges Investors With Losses To Connect As It Initiates Probe Into Lifecore Biomedical Inc
- LOS ANGELES, CA / ACCESSWIRE / June 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/23/2024
|
The Schall Law Firm Encourages Investors With Losses To Reach Out As It Begins Investigation Into Lifecore Biomedical Inc
- LOS ANGELES, CA / ACCESSWIRE / June 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/22/2024
|
The Schall Law Firm Urges Investors With Losses To Make Contact As It Initiates Probe Into Lifecore Biomedical Inc
- LOS ANGELES, CA / ACCESSWIRE / June 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/21/2024
|
The Schall Law Firm Encourages Investors With Losses To Reach Out As It Begins Investigation Into Lifecore Biomedical Inc
- LOS ANGELES, CA / ACCESSWIRE / June 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/20/2024
|
Lifecore Biomedical Inc Is Under Investigation The Schall Law Firm Urges Investors Who Have Incurred Losses To Make Contact
- LOS ANGELES, CA / ACCESSWIRE / June 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/19/2024
|
Lifecore Biomedical Inc Is Being Probed The Schall Law Firm Encourages Investors Who Have Suffered Losses To Reach Out
- LOS ANGELES, CA / ACCESSWIRE / June 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/18/2024
|
Lifecore Biomedical Inc Is Under Investigation The Schall Law Firm Urges Investors Who Have Incurred Losses To Make Contact
- LOS ANGELES, CA / ACCESSWIRE / June 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/17/2024
|
Lifecore Biomedical, Inc. Is Being Probed: The Schall Law Firm Encourages Investors Who Have Suffered Losses To Reach Out
- LOS ANGELES, CA / ACCESSWIRE / June 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/11/2024
|
An Investigation Is Being Conducted Into Lifecore Biomedical, Inc.: The Schall Law Firm Encourages Investors Who Have Suffered Losses To Get In Touch
- LOS ANGELES, CA / ACCESSWIRE / June 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/09/2024
|
Lifecore Biomedical, Inc. Is Under Investigation: The Schall Law Firm Invites Investors Who Have Experienced Losses To Contact Them
- LOS ANGELES, CA / ACCESSWIRE / June 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/08/2024
|
An Investigation Is Underway Into Lifecore Biomedical, Inc.: The Schall Law Firm Encourages Investors Who Have Suffered Losses To Reach Out
- LOS ANGELES, CA / ACCESSWIRE / June 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/07/2024
|
Lifecore Biomedical, Inc. Is Being Investigated: The Schall Law Firm Urges Investors Who Have Incurred Losses To Make Contact
- LOS ANGELES, CA / ACCESSWIRE / June 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/06/2024
|
Lifecore Biomedical, Inc. Under Investigation: Schall Law Firm Encourages Investors with Losses to Reach Out
- LOS ANGELES, CA / ACCESSWIRE / June 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/05/2024
|
The Schall Law Firm Initiates Investigation into Allegations Against Lifecore Biomedical, Inc. and Urges Investors Suffering Losses to Connect
- LOS ANGELES, CA / ACCESSWIRE / June 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/04/2024
|
LFCR INVESTIGATION PROGRESS UPDATE: The Schall Law Firm Announces it is Investigating Claims Against Lifecore Biomedical, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / June 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/03/2024
|
CRUCIAL INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Lifecore Biomedical, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / June 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/02/2024
|
CRUCIAL INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Lifecore Biomedical, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / June 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/01/2024
|
CRUCIAL INVESTIGATION UPDATE: The Schall Law Firm Announces it is Investigating Claims Against Lifecore Biomedical, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 05/31/2024
|
IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Lifecore Biomedical, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 05/30/2024
|
Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- CHASKA, Minn., May 22, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization, today announced that Lifecore has granted a restricted stock unit (“RSU”) award with respect to 525,000 shares of its common stock and a performance stock unit (“PSU”) award for up to 1,500,000 shares of its common stock to Paul Josephs, Lifecore's newly hired President and Chief Executive Officer. The RSU award and PSU award were granted May 20, 2024 pursuant to the Company's previously-announced offer letter with Mr. Josephs, and as a material inducement to Mr. Josephs joining Lifecore as President and Chief Executive Officer.
- 05/22/2024
|
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Lifecore Biomedical, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 05/19/2024
|
IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Lifecore Biomedical, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 05/18/2024
|
IMPORTANT SHAREHOLDER INVESTIGATION: The Schall Law Firm Announces it is Investigating Claims Against Lifecore Biomedical, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 05/17/2024
|
Lifecore Biomedical Completes Incremental Liquidity Initiatives
- Recent Initiatives Provide Approximately $8 Million of Non-Dilutive, Incremental Liquidity through Various Amendments with Lenders Recent Initiatives Provide Approximately $8 Million of Non-Dilutive, Incremental Liquidity through Various Amendments with Lenders
- 05/16/2024
|
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Lifecore Biomedical, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 05/16/2024
|
IMPORTANT INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Lifecore Biomedical, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 05/15/2024
|
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Lifecore Biomedical Inc. f/k/a Landec Corporation Investors to Inquire About Securities Class Action Investigation - LFCR, LNDC
- NEW YORK , May 13, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Lifecore Biomedical Inc. f/k/a Landec Corporation (NASDAQ: LFCR, LNDC) resulting from allegations that Lifecore Biomedical may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Lifecore Biomedical securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 05/13/2024
|
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Lifecore Biomedical Inc. f/k/a Landec Corporation Investors to Inquire About Securities Class Action Investigation - LFCR, LNDC
- NEW YORK , May 5, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Lifecore Biomedical Inc. f/k/a Landec Corporation (NASDAQ: LFCR, LNDC) resulting from allegations that Lifecore Biomedical may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Lifecore Biomedical securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 05/05/2024
|
IMPORTANT INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Lifecore Biomedical, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / April 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 04/30/2024
|
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Lifecore Biomedical Inc. f/k/a Landec Corporation Investors to Inquire About Securities Class Action Investigation - LFCR, LNDC
- NEW YORK , April 29, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Lifecore Biomedical Inc. f/k/a Landec Corporation (NASDAQ: LFCR, LNDC) resulting from allegations that Lifecore Biomedical may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Lifecore Biomedical securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 04/29/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Lifecore Biomedical, Inc. - LFCR
- NEW YORK , April 20, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ: LFCR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 04/20/2024
|
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Lifecore Biomedical Inc. f/k/a Landec Corporation Investors to Inquire About Securities Class Action Investigation - LFCR, LNDC
- NEW YORK , April 19, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Lifecore Biomedical Inc. f/k/a Landec Corporation (NASDAQ: LFCR, LNDC) resulting from allegations that Lifecore Biomedical may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Lifecore Biomedical securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 04/19/2024
|
Lifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delayed Quarterly Report
- CHASKA, Minn., April 19, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (the “Company”) announced today that, on April 15, 2024, the Company received a notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of the Company's delay in filing its Quarterly Report on Form 10-Q for the fiscal quarter ended February 25, 2024 (the “Q3 Form 10-Q”) and its continued delay in filing its Quarterly Report on Form 10-Q for the quarterly periods ended August 27, 2023 and November 29, 2023 (the “Q1 Form 10-Q” and “Q2 Form 10-Q,” respectively, and together with the Q3 Form 10-Q, the “Filings”) with the Securities and Exchange Commission (the “SEC”), the Company continues not to be in compliance with the requirements for continued listing under Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”), and that the Nasdaq Hearings Panel would consider the delinquency in the filing of the Q3 Form 10-Q in rendering its determination regarding the Company's continued listing on Nasdaq Global Select Market.
- 04/19/2024
|
LFCR INVESTOR NEWS: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Lifecore Biomedical Inc. f/k/a Landec Corporation Investors to Inquire About Securities Class Action Investigation - LFCR, LNDC
- NEW YORK , April 12, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Lifecore Biomedical Inc. f/k/a Landec Corporation (NASDAQ: LFCR, LNDC) resulting from allegations that Lifecore Biomedical may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Lifecore Biomedical securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 04/12/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Lifecore Biomedical, Inc. - LFCR
- NEW YORK , April 12, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ: LFCR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 04/12/2024
|
ROSEN, A TOP RANKED LAW FIRM, Encourages Lifecore Biomedical Inc. f/k/a Landec Corporation Investors to Inquire About Securities Class Action Investigation – LFCR, LNDC
- NEW YORK--(BUSINESS WIRE)---- $LFCR #LFCR--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Lifecore Biomedical Inc. f/k/a Landec Corporation (NASDAQ: LFCR, LNDC) resulting from allegations that Lifecore Biomedical may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Lifecore Biomedical securities you may be entitled to compensation without payment of any out of.
- 04/11/2024
|
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Lifecore Biomedical, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / April 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 04/11/2024
|
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Lifecore Biomedical, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / April 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 04/08/2024
|
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Lifecore Biomedical, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / April 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 04/05/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Lifecore Biomedical, Inc. - LFCR
- NEW YORK , April 4, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ: LFCR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 04/04/2024
|
ONGOING SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Lifecore Biomedical, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / April 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 04/04/2024
|
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Lifecore Biomedical, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / April 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 04/03/2024
|
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Lifecore Biomedical, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / April 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 04/01/2024
|
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Lifecore Biomedical, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / March 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ: LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 03/30/2024
|
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Lifecore Biomedical, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / March 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 03/29/2024
|
Lifecore (LFCR) Down 30% on Ending Strategic Review With No Deal
- Lifecore (LFCR) ends a year-long strategic review and will continue its operations on a stand-alone basis. The company also names a new CEO effective from May 20.
- 03/21/2024
|
Strength Seen in Lifecore Biomedical (LFCR): Can Its 16.0% Jump Turn into More Strength?
- Lifecore Biomedical (LFCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- 02/06/2024
|
Will Lifecore Biomedical (LFCR) Report Negative Q1 Earnings? What You Should Know
- Lifecore Biomedical (LFCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 09/28/2023
|
Lifecore Biomedical (LFCR) Reports Q4 Loss, Tops Revenue Estimates
- Lifecore Biomedical (LFCR) came out with a quarterly loss of $0.89 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.01 per share a year ago.
- 08/31/2023
|
Lifecore Biomedical Sets Fourth Quarter 2023 Earnings Conference Call for August 31, 2023 at 7:30 a.m. CT
- CHASKA, Minn., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it will host a conference call to discuss fiscal 2023 fourth quarter financial results. The live webcast can be accessed via Lifecore's website on the Investor Events & Presentations page. The webcast will be available for 30 days.
- 08/22/2023
|
QGEN vs. LFCR: Which Stock Is the Better Value Option?
- Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Qiagen (QGEN) or Lifecore Biomedical (LFCR). But which of these two stocks is more attractive to value investors?
- 07/07/2023
|
Lifecore: Highly Skewed Special Situation
- Lifecore Biomedical, Inc. is running a sale process. Laughing Water Capital believes upside of 150% is possible over the next three months. The Company's assets are highly strategic, and thus attractive to multiple potential buyers. Capacity will be doubling in the near term, and buyers have a track record of paying up for pending capacity in this industry.
- 06/27/2023
|
Lifecore Biomedical, Inc. (LFCR) Q3 2023 Earnings Call Transcript
- Lifecore Biomedical, Inc. (NASDAQ:LFCR ) Q3 2023 Earnings Conference Call June 1, 2023 8:30 AM ET Company Participants Jim Hall - President John Morberg - CFO Conference Call Participants Operator Good morning, and thank you for joining us today to discuss Lifecore Biomedical's Third Quarter Fiscal 2023 Earnings Results. Hosting the call today from the company are Jim Hall, President and Chief Executive Officer; and John Morberg, Chief Financial Officer.
- 06/01/2023
|
Lifecore Biomedical: Potential Company Sale
- Lifecore Biomedical jumped 50% yesterday after the company finally dispelled the previous going concern risk. Despite the share price jump, there are two other short-term catalysts here that could propel the share price much higher. One of those catalysts is a company sale.
- 05/24/2023
|
Lifecore Biomedical stock climbs 19% on $150 million refinancing deal
- Shares of Lifecore Biomedical on Monday climbed 19% to $6.40 in after-hours trading after the company said it secured a new $150 million financing agreement with its long-term customer Alcon.
- 05/22/2023
|
Lifecore Biomedical Sets Third Quarter 2023 Earnings Conference Call for June 1, 2023 at 7:30 a.m. CT
- CHASKA, Minn., May 22, 2023 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it will host a conference call to discuss fiscal 2023 third quarter financial results. The live webcast can be accessed via Lifecore's website on the Investor Events & Presentations page. The webcast will be available for 30 days.
- 05/22/2023
|
New Strong Sell Stocks for May 15th
- ARGO, PFSI and LFCR have been added to the Zacks Rank #5 (Strong Sell) List on May 15, 2023.
- 05/15/2023
|
Lifecore: Extraordinary Upside Likely Despite Bankruptcy Concerns
- Lifecore: Extraordinary Upside Likely Despite Bankruptcy Concerns.
- 04/20/2023
|
3 Penny Stocks To Buy According To Analysts, Targets Up To %170
- Penny stocks to buy according to 3 analysts. The post 3 Penny Stocks To Buy According To Analysts, Targets Up To %170 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 03/21/2023
|
High-Potential: A Short Guide to Penny Stock Investing
- Use these tips for finding high potential penny stocks The post High-Potential: A Short Guide to Penny Stock Investing appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 03/21/2023
|
4 Cheapest Defensive Stocks You Should Think About - Hempacco (NASDAQ:HPCO), Lifecore Biomedical (NASDAQ:LFCR)
- The most oversold stocks in the consumer staples sector presents an opportunity to buy into undervalued companies.
- 01/05/2023
|
New Strong Sell Stocks for December 23rd
- SGRP, LFCR and MD have been added to the Zacks Rank #5 (Strong Sell) List on December 23, 2022.
- 12/23/2022
|
